The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

NCT06019455 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Observational

Started

2022-06-01

Last updated

2024-12-10

Condition(s) studied

Lung CancerEsophageal Cancer

Study summary

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer. * Planned to undergo definitive chemoradiotherapy ± immunotherapy; * Males or females aged 18 to 75; * Able to communicate with medical staff. Exclusion Criteria: Patients with cognitive impairments.

Primary outcome measure(s)

Incidence of >=Grade 3 toxicities — 2 years
The percentage of patients who develop \>=Grade 3 toxicities

Trial sites (1)

Facility	City	Region	Status
Sun Yat-sen University	Guangzhou	China	Recruiting

More Sun Yat-sen University trials in China

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer Recruiting

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma Recruiting

Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma Active, not recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Other trials for the same condition

Research on Early Screening and Diagnosis of Pulmonary Nodules Based on Novel Non-invasive Technologies. Recruiting

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy Recruiting

A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring Recruiting

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Recruiting

Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06019455 on ClinicalTrials.gov ↗ ← All trials in China